{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:51:10Z","timestamp":1792799470155,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ23H300001"],"award-info":[{"award-number":["LQ23H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2022JKJNTZ12"],"award-info":[{"award-number":["2022JKJNTZ12"]}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2023JKZDZC03"],"award-info":[{"award-number":["2023JKZDZC03"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273861"],"award-info":[{"award-number":["82273861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Elite Scientists Sponsorship Program by China Association for Science and Technology","award":["YESS20220139"],"award-info":[{"award-number":["YESS20220139"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma (GBM) is the most aggressive primary brain tumor with low survival rate. Currently, temozolomide (TMZ) is the first-line drug for GBM treatment of which efficacy is unfortunately hindered by short circulation time and drug resistance associated to hypoxia and redox tumor microenvironment. Herein, a dual-targeted and multi-responsive nanoplatform is developed by loading TMZ in hollow manganese dioxide nanoparticles functionalized by polydopamine and targeting ligands RAP12 for photothermal and receptor-mediated dual-targeted delivery, respectively. After accumulated in GBM tumor site, the nanoplatform could respond to tumor microenvironment and simultaneously release manganese ion (Mn<jats:sup>2+<\/jats:sup>), oxygen (O<jats:sub>2<\/jats:sub>) and TMZ. The hypoxia alleviation via O<jats:sub>2<\/jats:sub> production, the redox balance disruption via glutathione consumption and the reactive oxygen species generation, together would down-regulate the expression of O<jats:sup>6<\/jats:sup>-methylguanine-DNA methyltransferase under TMZ medication, which is considered as the key to drug resistance. These strategies could synergistically alleviate hypoxia microenvironment and overcome TMZ resistance, further enhancing the anti-tumor effect of chemotherapy\/chemodynamic therapy against GBM. Additionally, the released Mn<jats:sup>2+<\/jats:sup> could also be utilized as a magnetic resonance imaging contrast agent for monitoring treatment efficiency. Our study demonstrated that this nanoplatform provides an alternative approach to the challenges including low delivery efficiency and drug resistance of chemotherapeutics, which eventually appears to be a potential avenue in GBM treatment.<\/jats:p>","DOI":"10.1186\/s12951-024-02531-3","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T05:01:55Z","timestamp":1715922115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaojie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2531_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","volume":"152","author":"C Alifieris","year":"2015","unstructured":"Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63\u201382.","journal-title":"Pharmacol Ther"},{"key":"2531_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Reviews Clin Oncol. 2018;15:422\u201342.","journal-title":"Nat Reviews Clin Oncol"},{"key":"2531_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.canlet.2020.01.027","volume":"475","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wu W, Bi H, Yang D, Zhang C. Glioblastoma precision therapy: from the bench to the clinic. Cancer Lett. 2020;475:79\u201391.","journal-title":"Cancer Lett"},{"key":"2531_CR4","doi-asserted-by":"publisher","first-page":"101790","DOI":"10.1016\/j.nantod.2023.101790","volume":"49","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang D, An Y, Sun Y, Li J, Zheng M, et al. Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma. Nano Today. 2023;49:101790.","journal-title":"Nano Today"},{"key":"2531_CR5","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.ajps.2023.100800","volume":"18","author":"Z Wang","year":"2023","unstructured":"Wang Z, Liu Z, Wang S, Bing X, Ji X, He D, et al. Implantation of hydrogel-liposome nanoplatform inhibits glioblastoma relapse by inducing ferroptosis. Asian J Pharm Sci. 2023;18:100800.","journal-title":"Asian J Pharm Sci"},{"key":"2531_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.4155\/fmc-2018-0521","volume":"11","author":"R Ortiz","year":"2019","unstructured":"Ortiz R, Cabeza L, Perazzoli G, Jimenez-Lopez J, Garcia-Pinel B, Melguizo C, et al. Nanoformulations for glioblastoma multiforme: a new hope for treatment. Future Med Chem. 2019;11:2461\u201382.","journal-title":"Future Med Chem"},{"key":"2531_CR7","doi-asserted-by":"publisher","first-page":"1705054","DOI":"10.1002\/adma.201705054","volume":"30","author":"C Qiao","year":"2018","unstructured":"Qiao C, Yang J, Shen Q, Liu R, Li Y, Shi Y, et al. Traceable nanoparticles with dual targeting and ROS response for RNAi-based immunochemotherapy of intracranial glioblastoma treatment. Adv Mater. 2018;30:1705054.","journal-title":"Adv Mater"},{"key":"2531_CR8","doi-asserted-by":"publisher","first-page":"2203958","DOI":"10.1002\/adma.202203958","volume":"34","author":"Y Zou","year":"2022","unstructured":"Zou Y, Wang Y, Xu S, Liu Y, Yin J, Lovejoy DB, et al. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater. 2022;34:2203958.","journal-title":"Adv Mater"},{"key":"2531_CR9","first-page":"2585","volume":"6","author":"HS Friedman","year":"2000","unstructured":"Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585\u201397.","journal-title":"Clin Cancer Res"},{"key":"2531_CR10","doi-asserted-by":"publisher","first-page":"11657","DOI":"10.1021\/acsami.1c00347","volume":"13","author":"L Meng","year":"2021","unstructured":"Meng L, Wang C, Lu Y, Sheng G, Yang L, Wu Z, et al. Targeted regulation of blood-brain barrier for enhanced therapeutic efficiency of hypoxia-modifier nanoparticles and immune checkpoint blockade antibodies for glioblastoma. ACS Appl Mater Interfaces. 2021;13:11657\u201371.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2531_CR11","doi-asserted-by":"publisher","first-page":"2007166","DOI":"10.1002\/adfm.202007166","volume":"31","author":"K Wang","year":"2021","unstructured":"Wang K, Kievit FM, Chiarelli PA, Stephen ZR, Lin G, Silber JR, et al. siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an Orthotopic Glioblastoma Xenograft Mouse Model. Adv Funct Mater. 2021;31:2007166.","journal-title":"Adv Funct Mater"},{"key":"2531_CR12","doi-asserted-by":"publisher","first-page":"39525","DOI":"10.1021\/acsami.9b13829","volume":"11","author":"W Fu","year":"2019","unstructured":"Fu W, You C, Ma L, Li H, Ju Y, Guo X, et al. Enhanced efficacy of temozolomide loaded by a tetrahedral framework DNA nanoparticle in the therapy for glioblastoma. ACS Appl Mater Interfaces. 2019;11:39525\u201333.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2531_CR13","doi-asserted-by":"publisher","first-page":"188616","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Et Biophys Acta-Reviews Cancer. 2021;1876:188616.","journal-title":"Biochim Et Biophys Acta-Reviews Cancer"},{"key":"2531_CR14","doi-asserted-by":"publisher","first-page":"2200095","DOI":"10.1002\/adtp.202200095","volume":"5","author":"Y Wang","year":"2022","unstructured":"Wang Y, Sun Y, Geng N, Zheng M, Zou Y, Shi B. A biomimetic nanomedicine targets orthotopic glioblastoma by combinatorial co-delivery of temozolomide and a methylguanine-DNA methyltransferase inhibitor. Adv Ther. 2022;5:2200095.","journal-title":"Adv Ther"},{"key":"2531_CR15","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s13277-013-0738-7","volume":"34","author":"M Taspinar","year":"2013","unstructured":"Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, et al. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Tumor Biol. 2013;34:1935\u201347.","journal-title":"Tumor Biol"},{"key":"2531_CR16","doi-asserted-by":"publisher","first-page":"10383","DOI":"10.1021\/nn503735w","volume":"8","author":"ZR Stephen","year":"2014","unstructured":"Stephen ZR, Kievit FM, Veiseh O, Chiarelli PA, Fang C, Wang K, et al. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O-6-Benzylguanine to Brain tumors. ACS Nano. 2014;8:10383\u201395.","journal-title":"ACS Nano"},{"key":"2531_CR17","doi-asserted-by":"publisher","first-page":"121608","DOI":"10.1016\/j.biomaterials.2022.121608","volume":"287","author":"M Ismail","year":"2022","unstructured":"Ismail M, Yang W, Li Y, Chai T, Zhang D, Du Q, et al. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. Biomaterials. 2022;287:121608.","journal-title":"Biomaterials"},{"key":"2531_CR18","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1039\/D2BM01145J","volume":"10","author":"Y Xie","year":"2022","unstructured":"Xie Y, Lu X, Wang Z, Liu M, Liu L, Wang R, et al. A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma. Biomaterials Sci. 2022;10:6791\u2013803.","journal-title":"Biomaterials Sci"},{"key":"2531_CR19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41419-018-1176-7","volume":"9","author":"X Ge","year":"2018","unstructured":"Ge X, Pan M-H, Wang L, Li W, Jiang C, He J, et al. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a\/Bad\/Bax axis. Cell Death Dis. 2018;9:1128.","journal-title":"Cell Death Dis"},{"key":"2531_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2019.12.041","volume":"319","author":"R Kumari","year":"2020","unstructured":"Kumari R, Sunil D, Ningthoujam RS. Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: an up-to-date review. J Control Release. 2020;319:135\u201356.","journal-title":"J Control Release"},{"key":"2531_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"2531_CR22","doi-asserted-by":"publisher","first-page":"2111171","DOI":"10.1002\/adfm.202111171","volume":"32","author":"Y Xing","year":"2022","unstructured":"Xing Y, Wang L, Wang L, Huang J, Wang S, Xie X, et al. Flower-like nanozymes with large accessibility of single atom catalysis sites for ROS generation boosted tumor therapy. Adv Funct Mater. 2022;32:2111171.","journal-title":"Adv Funct Mater"},{"key":"2531_CR23","doi-asserted-by":"crossref","unstructured":"Yang Y, Wu H, Liu B, Liu Z. Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Adv Drug Del Rev. 2021;179.","DOI":"10.1016\/j.addr.2021.114004"},{"key":"2531_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discovery. 2009;8:579\u201391.","journal-title":"Nat Rev Drug Discovery"},{"key":"2531_CR25","doi-asserted-by":"publisher","first-page":"1905823","DOI":"10.1002\/adma.201905823","volume":"32","author":"B Ding","year":"2020","unstructured":"Ding B, Zheng P, Ma P, Lin J. Manganese oxide nanomaterials: synthesis, properties, and theranostic applications. Adv Mater. 2020;32:1905823.","journal-title":"Adv Mater"},{"key":"2531_CR26","doi-asserted-by":"publisher","first-page":"2110092","DOI":"10.1002\/adfm.202110092","volume":"32","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Feng S, Hu G, Fang T, Xie D, Lu Q, et al. An adenovirus-mimicking photoactive nanomachine preferentially invades and destroys cancer cells through hijacking cellular glucose metabolism. Adv Funct Mater. 2022;32:2110092.","journal-title":"Adv Funct Mater"},{"key":"2531_CR27","doi-asserted-by":"publisher","first-page":"26557","DOI":"10.1021\/acsami.2c08413","volume":"14","author":"K Chen","year":"2022","unstructured":"Chen K, Li H, Zhou A, Zhou X, Xu Y, Ge H, et al. Cell membrane camouflaged metal oxide-black phosphorus biomimetic nanocomplex enhances photo-chemo-dynamic ferroptosis. ACS Appl Mater Interfaces. 2022;14:26557\u201370.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2531_CR28","doi-asserted-by":"publisher","first-page":"2104378","DOI":"10.1002\/adfm.202104378","volume":"31","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wen C, Sun Y-Q, Yu H, Yin X-B. Mixed-metal MOF-derived hollow porous nanocomposite for trimodality imaging guided reactive oxygen species-augmented synergistic therapy. Adv Funct Mater. 2021;31:2104378.","journal-title":"Adv Funct Mater"},{"key":"2531_CR29","doi-asserted-by":"publisher","first-page":"2109213","DOI":"10.1002\/adma.202109213","volume":"34","author":"C-Y Dong","year":"2022","unstructured":"Dong C-Y, Huang Q-X, Cheng H, Zheng D-W, Hong S, Yan Y, et al. Neisseria meningitidis opca Protein\/MnO2 hybrid nanoparticles for overcoming the blood-brain barrier to treat glioblastoma. Adv Mater. 2022;34:2109213.","journal-title":"Adv Mater"},{"key":"2531_CR30","doi-asserted-by":"publisher","first-page":"2101531","DOI":"10.1002\/smtd.202101531","volume":"6","author":"S Jiang","year":"2022","unstructured":"Jiang S, Li X, Zhang F, Mao J, Cao M, Zhang X, et al. Manganese dioxide-based nanocarrier delivers paclitaxel to enhance chemotherapy against orthotopic glioma through hypoxia relief. Small Methods. 2022;6:2101531.","journal-title":"Small Methods"},{"key":"2531_CR31","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1002\/wnan.1720","volume":"13","author":"G Yang","year":"2021","unstructured":"Yang G, Ji J, Liu Z. Multifunctional MnO2 nanoparticles for tumor microenvironment modulation and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13:e1720.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"2531_CR32","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41467-017-01050-0","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y, et al. Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017;8:902.","journal-title":"Nat Commun"},{"key":"2531_CR33","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.nantod.2022.101619","volume":"46","author":"N Yin","year":"2022","unstructured":"Yin N, Wang Y, Huang Y, Jin L, Zhang S, Liu J, et al. A biodegradable nanocapsule for through-skull NIR-II fluorescence imaging\/magnetic resonance imaging and selectively enhanced radio-chemotherapy for orthotopic glioma. Nano Today. 2022;46:101619.","journal-title":"Nano Today"},{"key":"2531_CR34","doi-asserted-by":"publisher","first-page":"2108263","DOI":"10.1002\/adma.202108263","volume":"34","author":"X Zhao","year":"2022","unstructured":"Zhao X, Guo K, Zhang K, Duan S, Chen M, Zhao N, et al. Orchestrated yolk-shell nanohybrids regulate macrophage polarization and dendritic cell maturation for oncotherapy with augmented antitumor immunity. Adv Mater. 2022;34:2108263.","journal-title":"Adv Mater"},{"key":"2531_CR35","doi-asserted-by":"publisher","first-page":"2003036","DOI":"10.1002\/advs.202003036","volume":"7","author":"J Tan","year":"2020","unstructured":"Tan J, Duan X, Zhang F, Ban X, Mao J, Cao M, et al. Theranostic nanomedicine for synergistic chemodynamic therapy and chemotherapy of Orthotopic Glioma. Adv Sci. 2020;7:2003036.","journal-title":"Adv Sci"},{"key":"2531_CR36","doi-asserted-by":"publisher","first-page":"20377","DOI":"10.1021\/acsnano.1c08689","volume":"15","author":"T Xiao","year":"2021","unstructured":"Xiao T, He M, Xu F, Fan Y, Jia B, Shen M, et al. Macrophage membrane-camouflaged responsive polymer nanogels enable magnetic resonance imaging-guided Chemotherapy\/Chemodynamic Therapy of Orthotopic Glioma. ACS Nano. 2021;15:20377\u201390.","journal-title":"ACS Nano"},{"key":"2531_CR37","doi-asserted-by":"publisher","first-page":"1900047","DOI":"10.1002\/adhm.201900047","volume":"8","author":"C Fu","year":"2019","unstructured":"Fu C, Duan X, Cao M, Jiang S, Ban X, Guo N, et al. Targeted magnetic resonance imaging and modulation of hypoxia with multifunctional hyaluronic acid-MnO2 nanoparticles in glioma. Adv Healthc Mater. 2019;8:1900047.","journal-title":"Adv Healthc Mater"},{"key":"2531_CR38","doi-asserted-by":"publisher","first-page":"124494","DOI":"10.1016\/j.cej.2020.124494","volume":"389","author":"W Zeng","year":"2020","unstructured":"Zeng W, Zhang H, Deng Y, Jiang A, Bao X, Guo M, et al. Dual-response oxygen-generating MnO2 nanoparticles with polydopamine modification for combined photothermal-photodynamic therapy. Chem Eng J. 2020;389:124494.","journal-title":"Chem Eng J"},{"key":"2531_CR39","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jconrel.2020.09.002","volume":"328","author":"GD Cha","year":"2020","unstructured":"Cha GD, Kang T, Baik S, Kim D, Choi SH, Hyeon T, et al. Advances in drug delivery technology for the treatment of glioblastoma multiforme. J Control Release. 2020;328:350\u201367.","journal-title":"J Control Release"},{"key":"2531_CR40","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/IJN.S243223","volume":"15","author":"J Li","year":"2020","unstructured":"Li J, Zhao J, Tan T, Liu M, Zeng Z, Zeng Y, et al. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J Nanomed. 2020;15:2563\u201382.","journal-title":"Int J Nanomed"},{"key":"2531_CR41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/pharmaceutics12111085","volume":"12","author":"H Luo","year":"2020","unstructured":"Luo H, Shusta EV. Blood-brain barrier modulation to improve glioma drug delivery. Pharmaceutics. 2020;12:1085.","journal-title":"Pharmaceutics"},{"key":"2531_CR42","doi-asserted-by":"publisher","first-page":"2302613","DOI":"10.1002\/smll.202302613","volume":"19","author":"X Song","year":"2023","unstructured":"Song X, Qian H, Yu Y. Nanoparticles mediated the diagnosis and therapy of glioblastoma: bypass or cross the blood-brain barrier. Small. 2023;19:2302613.","journal-title":"Small"},{"key":"2531_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ajps.2018.09.005","volume":"14","author":"X Niu","year":"2019","unstructured":"Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J Pharm Sci. 2019;14:480\u201396.","journal-title":"Asian J Pharm Sci"},{"key":"2531_CR44","doi-asserted-by":"publisher","first-page":"1903759","DOI":"10.1002\/adma.201903759","volume":"32","author":"H Wu","year":"2020","unstructured":"Wu H, Lu H, Xiao W, Yang J, Du H, Shen Y, et al. Sequential targeting in crosslinking nanotheranostics for tackling the multibarriers of brain tumors. Adv Mater. 2020;32:1903759.","journal-title":"Adv Mater"},{"key":"2531_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jconrel.2022.09.065","volume":"352","author":"T Li","year":"2022","unstructured":"Li T, Li J, Chen Z, Zhang S, Li S, Wageh S, et al. Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions. J Control Release. 2022;352:338\u201370.","journal-title":"J Control Release"},{"key":"2531_CR46","doi-asserted-by":"crossref","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct. Target. Ther. 2023;8:217.","DOI":"10.1038\/s41392-023-01481-w"},{"key":"2531_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","volume":"20","author":"K Mitusova","year":"2022","unstructured":"Mitusova K, Peltek OO, Karpov TE, Muslimov AR, Zyuzin MV, Timin AS. Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnol. 2022;20:412.","journal-title":"J Nanobiotechnol"},{"key":"2531_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2018.06.013","volume":"284","author":"C Praca","year":"2018","unstructured":"Praca C, Rai A, Santos T, Cristovao AC, Pinho SL, Cecchelli R, et al. A nanoformulation for the preferential accumulation in adult neurogenic niches. J Control Release. 2018;284:57\u201372.","journal-title":"J Control Release"},{"key":"2531_CR49","doi-asserted-by":"publisher","first-page":"1703458","DOI":"10.1002\/adma.201703458","volume":"30","author":"W Chen","year":"2018","unstructured":"Chen W, Ouyang J, Yi X, Xu Y, Niu C, Zhang W, et al. Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv Mater. 2018;30:1703458.","journal-title":"Adv Mater"},{"key":"2531_CR50","doi-asserted-by":"publisher","first-page":"1906050","DOI":"10.1002\/adma.201906050","volume":"32","author":"L Jin","year":"2020","unstructured":"Jin L, Hu P, Wang Y, Wu L, Qin K, Cheng H, et al. Fast-acting black-phosphorus-assisted depression therapy with low toxicity. Adv Mater. 2020;32:1906050.","journal-title":"Adv Mater"},{"key":"2531_CR51","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.drudis.2021.04.008","volume":"26","author":"S Reddy","year":"2021","unstructured":"Reddy S, Tatiparti K, Sau S, Iyer AK. Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors. Drug Discov Today. 2021;26:1944\u201352.","journal-title":"Drug Discov Today"},{"key":"2531_CR52","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1021\/nn203749v","volume":"6","author":"H Yan","year":"2012","unstructured":"Yan H, Wang L, Wang J, Weng X, Lei H, Wang X, et al. Two-order targeted brain tumor imaging by using an optical\/paramagnetic nanoprobe across the blood brain barrier. ACS Nano. 2012;6:410\u201320.","journal-title":"ACS Nano"},{"key":"2531_CR53","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.nano.2018.01.004","volume":"14","author":"D Liu","year":"2018","unstructured":"Liu D, Cheng Y, Cai R, Wang W, Cui H, Liu M, et al. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle. NNanomed-Nanotechnol. 2018;14:991\u20131003.","journal-title":"Nanomed-Nanotechnol"},{"key":"2531_CR54","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1515\/CCLM.2011.154","volume":"49","author":"M Franchini","year":"2011","unstructured":"Franchini M, Montagnana M. Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011;49:967\u201370.","journal-title":"Clin Chem Lab Med"},{"key":"2531_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fcell.2019.00031","volume":"7","author":"EE Bres","year":"2019","unstructured":"Bres EE, Faissner A. Low density receptor-related protein 1 interactions with the extracellular matrix: more than meets the eye. Front Cell Dev Biology. 2019;7:31.","journal-title":"Front Cell Dev Biology"},{"key":"2531_CR56","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1021\/mp100277h","volume":"7","author":"Z Pang","year":"2010","unstructured":"Pang Z, Feng L, Hua R, Chen J, Gao H, Pan S, et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm. 2010;7:1995\u20132005.","journal-title":"Mol Pharm"},{"key":"2531_CR57","doi-asserted-by":"publisher","first-page":"19038","DOI":"10.1021\/acsnano.2c08077","volume":"16","author":"Y Pan","year":"2022","unstructured":"Pan Y, Zhu Y, Xu C, Pan C, Shi Y, Zou J, et al. Biomimetic yolk-shell nanocatalysts for activatable dual-modal-image-guided triple-augmented chemodynamic therapy of cancer. ACS Nano. 2022;16:19038\u201352.","journal-title":"ACS Nano"},{"key":"2531_CR58","doi-asserted-by":"publisher","first-page":"2008540","DOI":"10.1002\/adma.202008540","volume":"33","author":"T He","year":"2021","unstructured":"He T, Jiang C, He J, Zhang Y, He G, Wu J, et al. Manganese-dioxide-coating-instructed plasmonic modulation of gold nanorods for activatable duplex-imaging-guided NIR-II photothermal-chemodynamic therapy. Adv Mater. 2021;33:2008540.","journal-title":"Adv Mater"},{"key":"2531_CR59","doi-asserted-by":"publisher","first-page":"133089","DOI":"10.1016\/j.cej.2021.133089","volume":"430","author":"Y Miao","year":"2022","unstructured":"Miao Y, Zhou X, Bai J, Zhao W, Zhao X. Hollow polydopamine spheres with removable manganese oxide nanoparticle caps for tumor microenvironment-responsive drug delivery. Chem Eng J. 2022;430:133089.","journal-title":"Chem Eng J"},{"key":"2531_CR60","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1021\/acsnano.2c09752","volume":"17","author":"Y Sun","year":"2023","unstructured":"Sun Y, Kong J, Ge X, Mao M, Yu H, Wang Y. An antisense oligonucleotide-loaded blood-brain barrier penetrable nanoparticle mediating recruitment of endogenous neural stem cells for the treatment of Parkinson\u2019s disease. ACS Nano. 2023;17:4414\u201332.","journal-title":"ACS Nano"},{"key":"2531_CR61","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/cmdc.202000263","volume":"15","author":"W Chen","year":"2020","unstructured":"Chen W, Chen Q, Chen Y, Zhang W, Huang Q, Hu M, et al. Acidity and glutathione dual-responsive polydopamine-coated organic-inorganic hybrid hollow mesoporous silica nanoparticles for controlled drug delivery. ChemMedChem. 2020;15:1940\u201346.","journal-title":"ChemMedChem"},{"key":"2531_CR62","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1002\/anie.201712027","volume":"57","author":"L-S Lin","year":"2018","unstructured":"Lin L-S, Song J, Song L, Ke K, Liu Y, Zhou Z, et al. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy. Angew Chem Int Ed. 2018;57:4902\u201306.","journal-title":"Angew Chem Int Ed"},{"key":"2531_CR63","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1021\/acsnano.8b01893","volume":"12","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhen W, Jin L, Zhang S, Sun G, Zhang T, et al. All-in-one theranostic nanoagent with enhanced reactive oxygen species generation and modulating tumor microenvironment ability for effective tumor eradication. ACS Nano. 2018;12:4886\u201393.","journal-title":"ACS Nano"},{"key":"2531_CR64","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcis.2021.02.054","volume":"592","author":"Y Miao","year":"2021","unstructured":"Miao Y, Feng Y, Bai J, Liu Z, Zhao X. Optimized mesoporous silica nanoparticle-based drug delivery system with removable manganese oxide gatekeeper for controlled delivery of doxorubicin. J Colloid Interface Sci. 2021;592:227\u201336.","journal-title":"J Colloid Interface Sci"},{"key":"2531_CR65","doi-asserted-by":"publisher","first-page":"9865","DOI":"10.7150\/thno.46771","volume":"10","author":"H Tang","year":"2020","unstructured":"Tang H, Li C, Zhang Y, Zheng H, Cheng Y, Zhu J, et al. Targeted manganese doped silica nano GSH-cleaner for treatment of liver cancer by destroying the intracellular redox homeostasis. Theranostics. 2020;10:9865\u201387.","journal-title":"Theranostics"},{"key":"2531_CR66","doi-asserted-by":"publisher","first-page":"eabm3381","DOI":"10.1126\/sciadv.abm3381","volume":"8","author":"D Wu","year":"2022","unstructured":"Wu D, Fei F, Zhang Q, Wang X, Gong Y, Chen X, et al. Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy. Sci Adv. 2022;8:eabm3381.","journal-title":"Sci Adv"},{"key":"2531_CR67","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2018.04.035","volume":"279","author":"H Ruan","year":"2018","unstructured":"Ruan H, Chai Z, Shen Q, Chen X, Su B, Xie C, et al. A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery. J Control Release. 2018;279:306\u201315.","journal-title":"J Control Release"},{"key":"2531_CR68","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.1038\/s41467-022-34462-8","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang D, Tian S, Liu Y, Zheng M, Yang X, Zou Y, et al. Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma. Nat Commun. 2022;13:6835.","journal-title":"Nat Commun"},{"key":"2531_CR69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nantod.2014.12.003","volume":"10","author":"T Liu","year":"2015","unstructured":"Liu T, Choi H, Zhou R, Chen IW. RES blockade: a strategy for boosting efficiency of nanoparticle drug. Nano Today. 2015;10:11\u201321.","journal-title":"Nano Today"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02531-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:06:26Z","timestamp":1715925986000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02531-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2531"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02531-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experiments were performed in conformity with the guidelines of the Zhejiang Chinese Medical University Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}